Pharmaceutical formulation comprising anti-EGFR antibody
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 16, 2021
Grant Date -
Dec 28, 2017
app pub date -
Jan 15, 2016
filing date -
Jan 19, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully